DOAC评分:房颤患者直接口服抗凝药出血风险预测工具的开发与验证
本研究基于RE-LY试验中5684例服用达比加群150mg每日两次的房颤患者开发DOAC评分,并在GARFIELD-AF、COMBINE-AF和RAMQ数据库中进行验证。DOAC评分在预测大出血方面优于HAS-BLED评分,各队列C统计量分别为0.73 vs 0.60、0.71 vs 0.66、0.67 vs 0.63和0.65 vs 0.58。
要点
- DOAC评分专为服用DOAC的房颤患者开发,预测大出血优于HAS-BLED评分。
- 每增加1分,大出血风险增加48.7%(95%CI 38.9%-59.3%,P<0.001)。
核心结论
- DOAC评分可帮助对可能适合DOAC治疗的房颤患者进行出血风险分层。
研究设计与样本
- RE-LY试验二次分析,纳入44个国家951个中心服用达比加群150mg每日两次的5684例患者,中位随访1.74年。
主要发现
- RE-LY中386例(6.8%)发生大出血事件。
- 内部验证后乐观校正C统计量为0.73,校准图视觉检查良好(拟合优度P=0.57)。
- DOAC评分在RE-LY中C统计量0.73 vs HAS-BLED 0.60(P<0.001)。
- COMBINE-AF中C统计量0.67 vs 0.63(P<0.001),RAMQ中0.65 vs 0.58(P<0.001)。
关键数值与推荐
- DOAC评分赋分因素包括年龄、肌酐清除率/肾小球滤过率、体重不足、卒中/短暂性脑缺血发作/栓塞史、糖尿病、高血压、抗血小板药物使用、非甾体抗炎药使用、肝病和出血史。
- 每增加1分与RE-LY中大出血风险增加48.7%(95%CI 38.9%-59.3%,P<0.001)相关。
临床怎么用
- 对于可能适合DOAC治疗的房颤患者,可使用DOAC评分评估预期出血风险以辅助分层管理。
局限性
- RE-LY分析仅基于达比加群150mg每日两次的患者。
- 外部验证队列的C统计量低于开发队列,判别性能中等。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Current clinical decision tools for assessing bleeding risk in individuals with atrial fibrillation (AF) have limited performance and were developed for individuals treated with warfarin. This study develops and validates a clinical risk score to personalize estimates of bleeding risk for individuals with atrial fibrillation taking direct-acting oral anticoagulants (DOACs). METHODS: Among individuals taking dabigatran 150 mg twice per day from 44 countries and 951 centers in this secondary analysis of the RE-LY trial (Randomized Evaluation of Long-Term Anticoagulation Therapy), a risk score was developed to determine the comparative risk for bleeding on the basis of covariates derived in a Cox proportional hazards model. The risk prediction model was internally validated with bootstrapping. The model was then further developed in the GARFIELD-AF registry (Global Anticoagulant Registry in the Field-Atrial Fibrillation), with individuals taking dabigatran, edoxaban, rivaroxaban, and apixaban. To determine generalizability in external cohorts and among individuals on different DOACs, the risk prediction model was validated in the COMBINE-AF (A Collaboration Between Multiple Institutions to Better Investigate Non-Vitamin K Antagonist Oral Anticoagulant Use in Atrial Fibrillation) pooled clinical trial cohort and the Quebec Régie de l'Assurance Maladie du Québec and Med-Echo Administrative Databases (RAMQ) administrative database. The primary outcome was major bleeding. The risk score, termed the DOAC Score, was compared with the HAS-BLED score. RESULTS: Of the 5684 patients in RE-LY, 386 (6.8%) experienced a major bleeding event, within a median follow-up of 1.74 years. The prediction model had an optimism-corrected C statistic of 0.73 after internal validation with bootstrapping and was well-calibrated based on visual inspection of calibration plots (goodness-of-fit P=0.57). The DOAC Score assigned points for age, creatinine clearance/glomerular filtration rate, underweight status, stroke/transient ischemic attack/embolism history, diabetes, hypertension, antiplatelet use, nonsteroidal anti-inflammatory use, liver disease, and bleeding history, with each additional point scored associated with a 48.7% (95% CI, 38.9%-59.3%; P<0.001) increase in major bleeding in RE-LY. The score had superior performance to the HAS-BLED score in RE-LY (C statistic, 0.73 versus 0.60; P for difference <0.001) and among 12 296 individuals in GARFIELD-AF (C statistic, 0.71 versus 0.66; P for difference = 0.025). The DOAC Score had stronger predictive performance than the HAS-BLED score in both validation cohorts, including 25 586 individuals in COMBINE-AF (C statistic, 0.67 versus 0.63; P for difference <0.001) and 11 945 individuals in RAMQ (C statistic, 0.65 versus 0.58; P for difference <0.001). CONCLUSIONS: In individuals with atrial fibrillation potentially eligible for DOAC therapy, the DOAC Score can help stratify patients on the basis of expected bleeding risk.
引用
- Aggarwal, Ruff, Virdone, et al. Development and Validation of the DOAC Score: A Novel Bleeding Risk Prediction Tool for Patients With Atrial Fibrillation on Direct-Acting Oral Anticoagulants. Circulation. 2023. PMID: 37621213. doi:10.1161/CIRCULATIONAHA.123.064556
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。